Nimodipin Hexal (Nimodipine)

Nimodipine, the active ingredient in Nimodipin Hexal, is a calcium channel blocker presented as an oral tablet for oral use. It helps prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients.

GNH USA supplies Nimodipin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is used to address vascular complications within the cerebral circulation, particularly after subarachnoid hemorrhage. - Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces the risk of delayed ischemic neurological deficits. - Management of delayed cerebral ischemia: lowers the incidence of secondary brain injury. - Support of neurological recovery after aneurysmal subarachnoid hemorrhage: contributes to improved functional outcomes.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: often positional. - Nausea or gastrointestinal discomfort. - Flushing: transient warmth of the skin. - Hypotension: mild blood pressure reduction. - Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Hepatic dysfunction: abnormal liver enzyme levels. - Allergic reactions: rash, pruritus, or angioedema. - Cardiac arrhythmias: irregular heart rhythms. - Hemorrhagic complications: rare bleeding events.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal impairment: adjust monitoring as clearance may be reduced. - Hepatic dysfunction: consider baseline liver function tests. - Concomitant antihypertensives: watch for additive blood pressure lowering. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Elderly patients: start at lower doses and titrate cautiously. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of toxicity. - Concurrent use with other potent vasodilators: can cause severe hypotension. - Nitrates: additive vasodilatory effect leading to dangerous blood pressure drops.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Beta‑blockers: may mask tachycardia signs of hypotension. - Diuretics: enhanced risk of electrolyte disturbances and low blood pressure.